Actavis CEO Says Health Law May Boost Generics Use

Feb. 15 (Bloomberg) -- Paul Bisaro, chief executive officer of Actavis Inc., talks about the impact of the U.S. Affordable Care Act on the pharmaceutical industry, so-called biosimilars, generic versions of biotechnology drugs, and the outlook for growth. He speaks with Mark Crumpton on Bloomberg Television's "Bottom Line." (Source: Bloomberg)

How to Impeach a President
40:37 - What does it actually take to remove a U.S. president from office? QuickTake Q&A explains the complex and rare process of impeachment. (Source: Bloomberg)
  • AEI's Rubin Says Trump Throws Away Rules on Budget
  • U.K. Police Say 23-Year-Old Arrested in Manchester Attack
  • U.K.'s Theresa May on Manchester Terror Attack